- Time:
A notable trend in the drug discovery industry is the growing diversity of therapeutic entity-types being developed. Applications of recent scientific discoveries have led to a range of novel, non-natural molecules, specifically designed to access disease target locations and binding sites that are challenging for traditional small molecule or natural biologic approaches. The development of these entities typically involves cross-functional teams of chemists and biologists. The diversity of novel entity types and the need to support cross-functional research teams places substantial burdens on an informatics system to support this science and has typically led to significant compromises in functionality and the ability to support both chemists and biologists. Too often, organizations have only been able to properly store chemical structures or biological sequences, or they try to combine them in systems that weren’t built for both. To be effective, an informatics system needs to be fully and natively fluent in both chemistry and biology.
In this GEN webinar, we will highlight key features of an informatics solution that supports research of novel, non-natural drug entities such as bicyclic and stapled peptides, antibody- and peptide-drug conjugates, and non-natural RNAs. Additionally, our presenters will demonstrate the scientific features of the Bioregister software from Dotmatics, which is dedicated to supporting this type of research.
A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.
Produced with support from:
Andrew LeBeau, PhD
Associate Vice President
of Biologics Marketing
Dotmatics
Troy Humphreys, PhD
Principal Application Scientist
Dotmatics
